{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:46:55Z","timestamp":1790077615237,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.beha.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T07:16:33Z","timestamp":1478330193000},"page":"99-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical features and management of non-gastrointestinal non-ocular extranodal mucosa associated lymphoid tissue (ENMALT) marginal zone lymphomas"],"prefix":"10.1016","volume":"30","author":[{"given":"Estella","family":"Matutes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.07.005_bib1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3","article-title":"Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B cell lymphoma","volume":"52","author":"Isaacson","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.07.005_bib2","series-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","article-title":"Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)","author":"Cook","year":"2008"},{"issue":"2","key":"10.1016\/j.beha.2016.07.005_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Arcaini","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2016.07.005_bib5","first-page":"167","article-title":"A\u00a0simple and effective MALT lymphoma-specific prognostic index generated from the dataset of the IELSG-19 controlled clinical trial","volume":"33","author":"Thieblemont","year":"2015","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib6","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2015-0180","article-title":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41)","volume":"20","author":"Jackson","year":"2015","journal-title":"Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine"},{"key":"10.1016\/j.beha.2016.07.005_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hed.23543","article-title":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009","volume":"37","author":"Vazquez","year":"2015","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.beha.2016.07.005_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijrobp.2010.09.046","article-title":"Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter rare cancer network study","volume":"82","author":"Anacak","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.beha.2016.07.005_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2004.04993.x","article-title":"Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection","volume":"126","author":"Ambrosetti","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.005_bib11","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1016\/j.ejrad.2011.12.035","article-title":"Mucosa-associated lymphoid tissue lymphoma of the salivary glands: MR imaging findings including diffusion-weighted imaging","volume":"81","author":"Katoa","year":"2012","journal-title":"Eur J Radiol"},{"issue":"9","key":"10.1016\/j.beha.2016.07.005_bib12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1080\/10428190701528509","article-title":"Primary salivary gland lymphoma among Japanese: a clinicopathological study of 30 cases","volume":"48","author":"Kojima","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.beha.2016.07.005_bib13","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2016.07.005_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2016.07.005_bib15","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2016.07.005_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.07.005_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1309\/AJCPNLC9NC9WTQYY","article-title":"Cutaneous B-Cell lymphoproliferative disorders. Report of the 2011 society for hematopathology\/European association for haematopathology workshop","volume":"139","author":"Swerdlow","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.beha.2016.07.005_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001\u20132009 with a focus on primary anatomic site","volume":"165","author":"Khalil","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.005_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2133.2009.09121.x","article-title":"Juvenile onset of primary low-grade cutaneous B-cell lymphoma","volume":"161","author":"Amitay-Laish","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2016.07.005_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1525-1470.2008.00843.x","article-title":"Two pediatric cases of primary cutaneous B-cell lymphoma and review of the literature","volume":"26","author":"Sharon","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.beha.2016.07.005_bib21","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B cell lymphomas. The Italian Study Group for cutaneous lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2016.07.005_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamadermatol.2013.9223","article-title":"High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-Cell lymphomas","volume":"150","author":"Guitart","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.beha.2016.07.005_bib23","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/modpathol.2008.159","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States","volume":"21","author":"Takino","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beha.2016.07.005_bib24","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1634\/theoncologist.2015-0175","article-title":"Primary cutaneous B-cell lymphoma: management and patterns of recurrence at the multimodality Cutaneous Lymphoma clinic of the Ohio State University","volume":"20","author":"Haverkos","year":"2015","journal-title":"Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.beha.2016.07.005_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/DAD.0b013e318267495f","article-title":"Blastic marginal zone lymphoma: a clinical and pathological study of 8 cases and review of the literature","volume":"35","author":"Magro","year":"2013","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.beha.2016.07.005_bib27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2141.2011.08606.x","article-title":"Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease","volume":"153","author":"Watanabe","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.005_bib28","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1210\/jc.2013-1428","article-title":"Primary thyroid lymphoma: a clinical review","volume":"98","author":"Stein","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beha.2016.07.005_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4174\/astr.2015.89.6.295","article-title":"Clinicopathological characteristics and treatment outcomes of 38 cases of primary thyroid lymphoma: a multicenter study","volume":"89","author":"Chai","year":"2015","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.beha.2016.07.005_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000333113","article-title":"Primary thyroid marginal zone B-Cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease \u2013 consortium for improving survival of lymphoma study","volume":"127","author":"Oh","year":"2012","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.beha.2016.07.005_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00000478-200005000-00001","article-title":"Malignant lymphoma of the thyroid gland. A clinicopathologic study of 108 cases","volume":"24","author":"Derringer","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beha.2016.07.005_bib32","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.surg.2009.09.020","article-title":"Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases","volume":"146","author":"Graff-Baker","year":"2009","journal-title":"Surgery"},{"key":"10.1016\/j.beha.2016.07.005_bib33","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1634\/theoncologist.2013-0036","article-title":"Thyroid lymphoma: recent advances in diagnosis and optimal management Strategies","volume":"18","author":"Walsh","year":"2013","journal-title":"Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib34","series-title":"WHO classification of tumours. Pathology and genetics. Tumours of the lung, pleura, thymus and heart","first-page":"88","article-title":"Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type","author":"Nicholson","year":"2004"},{"issue":"6","key":"10.1016\/j.beha.2016.07.005_bib35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.12703","article-title":"Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe","volume":"164","author":"Adam","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.07.005_bib36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1183\/09031936.00039309","article-title":"Clinical characteristics and prognostic factors of pulmonary MALT lymphoma","volume":"34","author":"Zinzani","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.beha.2016.07.005_bib37","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1183\/09031936.00039309","article-title":"I.\u00a0Clinical characteristics and prognostic factors of Pulmonary MALT lymphoma","volume":"34","author":"Borie","year":"2009","journal-title":"Eur Resp J"},{"issue":"6","key":"10.1016\/j.beha.2016.07.005_bib38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-009-0875-7","article-title":"Pulmonary marginal zone B-cell lymphoma of MALT type\u2013what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"89","author":"Oh","year":"2010","journal-title":"Ann Hematol"},{"issue":"5B","key":"10.1016\/j.beha.2016.07.005_bib39","first-page":"3633","article-title":"Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up","volume":"27","author":"Troch","year":"2007","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.beha.2016.07.005_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hon.2039","article-title":"Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens","volume":"31","author":"Zinzani","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hon.2008","article-title":"Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population","volume":"31","author":"Ogusa","year":"2013","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.07.005_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22753","article-title":"Non-Hodgkin lymphoma of the breast","volume":"110","author":"Ganjoo","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2016.07.005_bib43","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/annonc\/mdp238","article-title":"Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group","volume":"20","author":"Martinelli","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.beha.2016.07.005_bib44","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00277-003-0664-7","article-title":"Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews","volume":"82","author":"Kuper-Hommel","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.07.005_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1477-7819-8-53","article-title":"Primary breast lymphomas: a multicentric experience","volume":"8","author":"Avenia","year":"2010","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib46","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3109\/10428194.2013.771399","article-title":"Extranodal marginal zone lymphoma of the cranial dura: report of three cases and systematic review of the literature","volume":"54","author":"Beltran","year":"2013","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.beha.2016.07.005_bib47","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1200\/JCO.2005.17.624","article-title":"Clinicopathologic and genetic profile of intracranial marginal zone lymphoma. A primary low grade CNS lymphoma that mimics meningioma","volume":"23","author":"Tu","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.07.005_bib48","doi-asserted-by":"crossref","first-page":"327917","DOI":"10.1155\/2014\/327917","article-title":"Lymphoma of the urinary bladder","volume":"2014","author":"Venyo","year":"2014","journal-title":"Adv Urol"},{"key":"10.1016\/j.beha.2016.07.005_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1309\/0T2UKUKV91W3QR6W","article-title":"MALT lymphomas involving the kidney","volume":"128","author":"Garcia","year":"2007","journal-title":"Am J Clin Path"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T09:25:24Z","timestamp":1568539524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":49,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1521692616300858"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.07.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and management of non-gastrointestinal non-ocular extranodal mucosa associated lymphoid tissue (ENMALT) marginal zone lymphomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}